Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Carcinoma, Non-Small-Cell Lung 199Breast Neoplasms 136Prostatic Neoplasms 72Neoplasms 62Neoplasm Metastasis 52Lung Neoplasms 45Stomach Neoplasms 27Parkinson Disease 4, Autosomal Dominant Lewy Body 22Squamous Cell Carcinoma of Head and Neck 17Ovarian Neoplasms 15Advanced Solid Tumors 14Recurrence 12Head and Neck Neoplasms 11Colorectal Neoplasms 11Carcinoma, Squamous Cell 11Urinary Bladder Neoplasms 10Melanoma 10Esophageal Neoplasms 10HER2-positive Breast Cancer 9Endometrial Neoplasms 9Carcinoma, Renal Cell 9Sarcoma 8Esophageal Squamous Cell Carcinoma 8Carcinoma, Transitional Cell 8Solid Tumor 7Prostatic Neoplasms, Castration-Resistant 7Pancreatic Neoplasms 7Carcinoma 7Triple Negative Breast Neoplasms 6Small Cell Lung Carcinoma 6

Interventions

Erlotinib Hydrochloride 21Bevacizumab 13Cisplatin 12Carboplatin 7Pemetrexed 6Gemcitabine 6Paclitaxel 5onartuzumab 4Docetaxel 3imgatuzumab 2sintilimab 1parsatuzumab 1lifastuzumab vedotin 1atezolizumab 1Vinorelbine 1RG-1507 monoclonal antibody 1Platinum Compounds 1Etoposide 12-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine 12,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Non-Squamous Non-Small Cell Lung Cancer × Docetaxel × Clear all
NCT02008227 2019-12-20

OAK

Hoffmann-La Roche

Phase 3 Completed
1,225 enrolled 32 charts
Thoracic

Non-Squamous Non-Small Cell Lung Cancer

NCT01351415 2017-09-18

A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)

Hoffmann-La Roche

Phase 3 Completed
485 enrolled 15 charts
Thoracic

Non-Squamous Non-Small Cell Lung Cancer

NCT01204697 2015-11-16

A Study of Erlotinib [Tarceva] as Monotherapy or Intermittent Dosing With Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer. (TALISMAN)

Hoffmann-La Roche

Phase 2 Completed
74 enrolled 12 charts
Thoracic

Non-Squamous Non-Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡